Literature DB >> 23269992

Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.

Sebastian Theurich1, Joke Malcher, Kerstin Wennhold, Alexander Shimabukuro-Vornhagen, Jens Chemnitz, Udo Holtick, Anke Krause, Carsten Kobe, Deniz Kahraman, Andreas Engert, Christof Scheid, Geothy Chakupurakal, Michael Hallek, Michael von Bergwelt-Baildon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23269992     DOI： 10.1200/JCO.2012.43.6832

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.

Authors:  Carmelo Carlo-Stella; Francesca Ricci; Serena Dalto; Rita Mazza; Michele Malagola; Francesca Patriarca; Simonetta Viviani; Domenico Russo; Laura Giordano; Luca Castagna; Paolo Corradini; Armando Santoro
Journal:  Oncologist       Date:  2015-02-10

2.  Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.

Authors:  L Castagna; B Sarina; R Crocchiolo; S Bramanti; S Furst; R Devillier; D Coso; R Bouabdallah; D Mokart; L Morabito; S Harbi; L Giordano; A Rimondo; P Jean Weiller; C Carlo-Stella; A Santoro; C Chabannon; D Blaise
Journal:  Bone Marrow Transplant       Date:  2016-10-17       Impact factor: 5.483

Review 3.  Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!

Authors:  M A Kharfan-Dabaja; M Hamadani; H Sibai; B N Savani
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

4.  OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation.

Authors:  Udo Holtick; Jens-Markus Chemnitz; Alexander Shimabukuro-Vornhagen; Sebastian Theurich; Geothy Chakupurakal; Anke Krause; Anne Fiedler; Leo Luznik; Martin Hellmich; Dominik Wolf; Michael Hallek; Michael von Bergwelt-Baildon; Christof Scheid
Journal:  Eur J Haematol       Date:  2015-03-16       Impact factor: 2.997

Review 5.  Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.

Authors:  Solomon A Graf; Ajay K Gopal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

6.  Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.

Authors:  Philipp Müller; Kea Martin; Sebastian Theurich; Michael von Bergwelt-Baildon; Alfred Zippelius
Journal:  Oncoimmunology       Date:  2014-08-03       Impact factor: 8.110

7.  Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party.

Authors:  Nicole Santoro; Jarl E Mooyaart; Raynier Devillier; Yener Koc; Jan Vydra; Luca Castagna; Zafer Gülbas; José Diez Martin; Mercedes Colorado Araujo; Alexander Kulagin; Mutlu Arat; Concepcion Herrera Arroyo; Maria Paola Martelli; Mauro Di Ianni; Jorinde D Hoogenboom; Liesbeth C de Wreede; Annalisa Ruggeri; Christian Chabannon
Journal:  Bone Marrow Transplant       Date:  2022-10-10       Impact factor: 5.174

Review 8.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

9.  Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation.

Authors:  P Tsirigotis; I Danylesko; K Gkirkas; N Shem-Tov; R Yerushalmi; M Stamouli; A Avigdor; A Spyridonidis; J Gauthier; G Goldstein; J Apostolidis; M Mohty; A Shimoni; A Nagler
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483

10.  Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.

Authors:  Aurore Perrot; Hélène Monjanel; Réda Bouabdallah; Philippe Quittet; Clémentine Sarkozy; Marc Bernard; Aspasia Stamatoullas; Cécile Borel; Krimo Bouabdallah; Emmanuelle Nicolas-Virelizier; Marion Fournier; Franck Morschhauser; Pauline Brice
Journal:  Haematologica       Date:  2016-01-14       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.